LearnBonds.com

Abbott Laboratories Stock Price Presents a Long Term Buying Opportunity

Abbott Laboratories Stock Price Presents a Long Term Buying Opportunity
5 (100%) 1 vote[s]

Abbott Laboratories (NYSE: ABT) stock price rallied 17% this year. The shares are up almost 100% in the past three years. The substantial stock price gains are backed by its innovations in medical devices, diagnostics, and pharmaceutical products.

ABT Abbott Laboratories weekly Stock Chart

The sustainable growth in revenue and earnings has also been adding to Abbott Laboratories stock price gains. The company has generated mid-single-digit revenue and double-digit earnings growth in the past three years.

The company’s strategy of offering big cash returns in the form of dividends are helping in optimizing investors sentiments.

Abbot Laboratories currently offers a quarterly dividend of $0.32 per share, yielding around 1.56%.

The company had increased its quarterly dividend by 14% last year. It has increased dividends in the past 47 successive years. Abbott is the member of Dividend Aristocrats Index. It has paid dividends in the past 380 consecutive quarters.

Its organic revenue grew 7.6% year over year in the latest quarter. Its adjusted EPS of $0.82 increased at a double-digit rate from the past year period.

Our sales growth accelerated and are sustainable,” said Miles D. White, chairman, and chief executive officer, Abbott. “We have great momentum and are raising our guidance above the strong outlook we previously set for the year.”

Abbott has raised its full-year earnings outlook following higher than expected results in the first half.

The company now expects full-year adjusted diluted earnings per share from continuing operations in the range of $3.21 to $3.27. This indicates a double-digit growth from the previous year. It also expects organic revenue growth around 7.0 to 8.0 percent for fiscal 2019.

Abbott Laboratories stock price has also been receiving support from share buybacks. In addition, the share repurchase program enhances earnings per share and dividend per share. Overall, Abbott Laboratories stock is likely to extend momentum in the coming days. It’s a good stock for defensive investors who are seeking steady growth in dividend and share price.

Views expressed are those of the writers only. Past performance is no guarantee of future results. Trading comes with severe risk. The opinions expressed in this Site do not constitute investment advice and independent financial advice should be sought where appropriate. This website is free for you to use but we may receive commission from the companies we feature on this site.
Avatar

siraj sarwar

Based in Saudi Arabia, Siraj has a strong understanding of and passion for accounting and finance. He has worked for international clients for many years on several projects related to the stock market, equity research and other business, accounting and finance related projects. Siraj is a published financial analyst on the world's leading websites including SeekingAlpha, TheStreet, MSN, and others.

Write first comment

Reply

Your email address is not published.